Clinical Trial Details
| Trial ID: | L4417 |
| Source ID: | NCT05915949 |
| Associated Drug: | Dapagliflozin 10mg Tab |
| Title: | Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety |
| Acronym: | Location-F |
| Status: | RECRUITING |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetes Type 2 |
| Interventions: | DRUG: Dapagliflozin 10mg Tab|DRUG: Lobeglitazone 0.5 mg|DRUG: Dapagliflozin + Lobeglitazone |
| Outcome Measures: | Primary: HbA1c, Glycemic control, 6 months | Secondary: Fasting plasma glucose, Glucose metabolism, 6 months|Postprandial glucose, Glucose metabolism, 6 months|Whole body muscle, Body composition, 6 months|Whole body fat, Body composition, 6 months|Abdominal subcutaneous fat, Body composition, 6 months|Abdominal visceral fat, Body composition, 6 months|NTproBNP, Cardiac marker, 6 months|Troponin T, Cardiac marker, 6 months|Lipids, Lipid profiles (TG, HDL, and LDL), 6 months|Lipoprotein (a), Lipid metabolism, 6 months|Urinary microalbumin-Creatinine ratio, Lipid metabolism, 6 months|Fib-4, Hepatic fibrosis marker, 6 months | Other: Adverse events, Side effects., 6 months |
| Sponsor/Collaborators: | Sponsor: Seoul National University Bundang Hospital |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE4 |
| Enrollment: | 99 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT |
| Start Date: | 2022-01-01 |
| Completion Date: | 2023-12-31 |
| Results First Posted: | |
| Last Update Posted: | 2023-08-14 |
| Locations: | Seoul National University Bundang Hospital, Seongnam, Gyeonggi, 463-707, Korea, Republic of |
| URL: | https://clinicaltrials.gov/show/NCT05915949 |
